The DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index.
Complement in cancer: untangling an intricate relationship
Open accessAbstract
In tumour immunology, complement has traditionally been considered as an adjunctive component that enhances the cytolytic effects of antibody-based immunotherapies, such as rituximab. Remarkably, research in the past decade has uncovered novel molecular mechanisms linking imbalanced complement activation in the tumour microenvironment with inflammation and suppression of antitumour immune responses. These findings have prompted new interest in manipulating the complement system for cancer therapy. This Review summarizes our current understanding of complement-mediated effector functions in the tumour microenvironment, focusing on how complement activation can act as a negative or positive regulator of tumorigenesis. It also offers insight into clinical aspects, including the feasibility of using complement biomarkers for cancer diagnosis and the use of complement inhibitors during cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Self-citationElements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Complement factor H polymorphism in age-related macular degeneration
Klein, R. J., Zeiss, C., Chew, E. Y., Tsai, J.-Y., Sackler, R. S., Haynes, C., Henning, A. K., SanGiovanni, J. P., Mane, S. M., Mayne, S. T., et al. (2005) · Science · doi:10.1126/science.1109557 · Cited by 4,492
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033
Self-citationComplement: a key system for immune surveillance and homeostasis
Ricklin, D., Hajishengallis, G., Yang, K., & Lambris, J. D. (2010) · Nature Immunology · doi:10.1038/ni.1923 · Cited by 3,654
Self-citationThe global health burden of infection‐associated cancers in the year 2002
Parkin, D. M. (2006) · International Journal of Cancer · doi:10.1002/ijc.21731 · Cited by 2,932
Complement factor H polymorphism and age-related macular degeneration
Edwards, A. O., Ritter, R., Abel, K. J., Manning, A., Panhuysen, C., & Farrer, L. A. (2005) · Science · doi:10.1126/science.1110189 · Cited by 2,449
Complement factor H variant increases the risk of age-related macular degeneration
Haines, J. L., Hauser, M. A., Schmidt, S., Scott, W. K., Olson, L. M., Gallins, P., Spencer, K. L., Kwan, S. Y., Noureddine, M., Gilbert, J. R., et al. (2005) · Science · doi:10.1126/science.1110359 · Cited by 2,424
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Maloney, D. G., Grillo-López, A. J., White, C. A., Bodkin, D., Schilder, R. J., Neidhart, J. A., Janakiraman, N., Foon, K. A., Liles, T.-M., Dallaire, B. K., et al. (1997) · Blood · doi:10.1182/blood.v90.6.2188 · Cited by 1,733
Complement regulators and inhibitory proteins
Zipfel, P. F., & Skerka, C. (2009) · Nature Reviews Immunology · doi:10.1038/nri2620 · Cited by 1,264
C3d of complement as a molecular adjuvant: Bridging innate and acquired immunity
Dempsey, P. W., Allison, M. E. D., Akkaraju, S., Goodnow, C. C., & Fearon, D. T. (1996) · Science · doi:10.1126/science.271.5247.348 · Cited by 1,197
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117
The Complement System: An Unexpected Role in Synaptic Pruning During Development and Disease
Stephan, A. H., Barres, B. A., & Stevens, B. (2012) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113810 · Cited by 1,113
de Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037
Prospects for combining targeted and conventional cancer therapy with immunotherapy
Gotwals, P., Cameron, S., Cipolletta, D., Cremasco, V., Crystal, A., Hewes, B., Mueller, B., Quaratino, S., Sabatos-Peyton, C., Petruzzelli, L., et al. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.17 · Cited by 953
Radiation-induced bystander signalling in cancer therapy
Prise, K. M., & O'Sullivan, J. M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2603 · Cited by 810
Complement Is Activated by IgG Hexamers Assembled at the Cell Surface
Diebolder, C. A., Beurskens, F. J., de Jong, R. N., Koning, R. I., Strumane, K., Lindorfer, M. A., Voorhorst, M., Ugurlar, D., Rosati, S., Heck, A. J. R., et al. (2014) · Science · doi:10.1126/science.1248943 · Cited by 796
Modulation of the antitumor immune response by complement
Markiewski, M. M., DeAngelis, R. A., Benencia, F., Ricklin-Lichtsteiner, S. K., Koutoulaki, A., Gerard, C., Coukos, G., & Lambris, J. D. (2008) · Nature Immunology · doi:10.1038/ni.1655 · Cited by 778
Self-citationDifferential exoprotease activities confer tumor-specific serum peptidome patterns
Villanueva, J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26022 · Cited by 741
Molecular Intercommunication between the Complement and Coagulation Systems
Amara, U., Flierl, M. A., Rittirsch, D., Klos, A., Chen, H., Acker, B., Brückner, U. B., Nilsson, B., Gebhard, F., Lambris, J. D., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903678 · Cited by 720
Self-citationImmunity, inflammation, and cancer: an eternal fight between good and evil
Shalapour, S., & Karin, M. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80007 · Cited by 698
Cancer-related inflammation: Common themes and therapeutic opportunities
Balkwill, F. R., & Mantovani, A. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.12.005 · Cited by 685
Self-citationLiszewski, M. K., Kolev, M., Le Friec, G., Leung, M., Bertram, P. G., Fara, A. F., Subias, M., Pickering, M. C., Drouet, C., Meri, S., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.018 · Cited by 582
Strainic, M. G., Liu, J., Huang, D., An, F., Lalli, P. N., Muqim, N., Shapiro, V. S., Dubyak, G. R., Heeger, P. S., & Medof, M. E. (2008) · Immunity · doi:10.1016/j.immuni.2008.02.001 · Cited by 580
Innate Immune Recognition of Cancer
Woo, S.-R., Corrales, L., & Gajewski, T. F. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112043 · Cited by 571
Complement in disease: a defence system turning offensive
Ricklin, D., Reis, E. S., & Lambris, J. D. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.70 · Cited by 550
Self-citationT helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4 + T cells
Arbore, G., West, E. E., Spolski, R., Robertson, A. A. B., Klos, A., Rheinheimer, C., Dutow, P., Woodruff, T. M., Yu, Z. X., O’Neill, L. A., et al. (2016) · Science · doi:10.1126/science.aad1210 · Cited by 513
Production of complement components by cells of the immune system
Lubbers, R., van Essen, M. F., van Kooten, C., & Trouw, L. A. (2017) · Clinical and Experimental Immunology · doi:10.1111/cei.12952 · Cited by 480
Damage-associated molecular patterns in cancer: a double-edged sword
Hernandez, C., Huebener, P., & Schwabe, R. F. (2016) · Oncogene · doi:10.1038/onc.2016.104 · Cited by 480
Complement in Immune and Inflammatory Disorders: Pathophysiological Mechanisms
Ricklin, D., & Lambris, J. D. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203487 · Cited by 478
Self-citationRadiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell Activation
Gupta, A., Probst, H. C., Vuong, V., Landshammer, A., Muth, S., Yagita, H., Schwendener, R., Pruschy, M., Knuth, A., & van den Broek, M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200563 · Cited by 446
The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression
Umansky, V., Blattner, C., Gebhardt, C., & Utikal, J. (2016) · Vaccines · doi:10.3390/vaccines4040036 · Cited by 438
Complement, a target for therapy in inflammatory and degenerative diseases
Morgan, B. P., & Harris, C. L. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4657 · Cited by 431
Golay, J., Lazzari, M., Facchinetti, V., Bernasconi, S., Borleri, G., Barbui, T., Rambaldi, A., & Introna, M. (2001) · Blood · doi:10.1182/blood.v98.12.3383 · Cited by 428
PTX3 Is an Extrinsic Oncosuppressor Regulating Complement-Dependent Inflammation in Cancer
Bonavita, E., Gentile, S., Rubino, M., Maina, V., Papait, R., Kunderfranco, P., Greco, C., Feruglio, F., Molgora, M., Laface, I., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.004 · Cited by 417
Self-citationRegulation of Humoral Immunity by Complement
Carroll, M. C., & Isenman, D. E. (2012) · Immunity · doi:10.1016/j.immuni.2012.08.002 · Cited by 387
In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas
Manches, O., Lui, G., Chaperot, L., Gressin, R., Molens, J.-P., Jacob, M.-C., Sotto, J.-J., Leroux, D., Bensa, J.-C., & Plumas, J. (2003) · Blood · doi:10.1182/blood-2002-02-0469 · Cited by 372
Complement Component 3 adapts the cerebrospinal fluid for leptomeningeal metastasis.
Boire, A., Zou, Y., Shieh, J., Macalinao, D. G., Pentsova, E., & Massagué, J. (2017) · Cell · doi:10.1016/j.cell.2017.02.025 · Cited by 366
Bresin, E., Rurali, E., Caprioli, J., Sanchez-Corral, P., Fremeaux-Bacchi, V., Rodriguez de Cordoba, S., Pinto, S., Goodship, T. H. J., Alberti, M., Ribes, D., et al. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012090884 · Cited by 352
Extrahepatic complement biosynthesis: where, when and why?
Morgan, B. P., & Gasque, P. (2003) · Clinical and Experimental Immunology · doi:10.1046/j.1365-2249.1997.d01-890.x · Cited by 351
Complement driven by conformational changes
Gros, P., Milder, F. J., & Janssen, B. J. C. (2008) · Nature Reviews Immunology · doi:10.1038/nri2231 · Cited by 323
Strainic, M. G., Shevach, E. M., An, F., Lin, F., & Medof, M. E. (2013) · Nature Immunology · doi:10.1038/ni.2499 · Cited by 302
Ross, G. D., Yount, W. J., Walport, M. J., Winfield, J. B., Parker, C. J., Fuller, C. R., Taylor, R. P., Myones, B. L., & Lachmann, P. J. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.3.2005 · Cited by 300
Bulla, R., Tripodo, C., Rami, D., Ling, G. S., Agostinis, C., Guarnotta, C., Zorzet, S., Durigutto, P., Botto, M., & Tedesco, F. (2016) · Nature Communications · doi:10.1038/ncomms10346 · Cited by 294
Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer
Hughes, P. E., Caenepeel, S., & Wu, L. C. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.04.010 · Cited by 282
Anaphylatoxin C5a Creates a Favorable Microenvironment for Lung Cancer Progression
Corrales, L., Ajona, D., Rafail, S., Lasarte, J. J., Riezu-Boj, J. I., Lambris, J. D., Rouzaut, A., Pajares, M. J., Montuenga, L. M., & Pio, R. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201654 · Cited by 281
Self-citationMutations in lectin complement pathway genes COLEC11 and MASP1 cause 3MC syndrome
Rooryck, C., Diaz-Font, A., Osborn, D. P. S., Chabchoub, E., Hernandez-Hernandez, V., Shamseldin, H., Kenny, J., Waters, A., Jenkins, D., Kaissi, A. A., et al. (2011) · Nature Genetics · doi:10.1038/ng.757 · Cited by 264
Cockburn, I. A., Mackinnon, M. J., O'Donnell, A., Allen, S. J., Moulds, J. M., Baisor, M., Bockarie, M., Reeder, J. C., & Rowe, J. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0305306101 · Cited by 255
Guglietta, S., Chiavelli, A., Zagato, E., Krieg, C., Gandini, S., Ravenda, P. S., Bazolli, B., Lu, B., Penna, G., & Rescigno, M. (2016) · Nature Communications · doi:10.1038/ncomms11037 · Cited by 255
A Combined PD-1/C5a Blockade Synergistically Protects against Lung Cancer Growth and Metastasis
Ajona, D., Ortiz-Espinosa, S., Moreno, H., Lozano, T., Pajares, M. J., Agorreta, J., Bértolo, C., Lasarte, J. J., Vicent, S., Hoehlig, K., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1184 · Cited by 247
Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor
Longhurst, H., Cicardi, M., Craig, T., Bork, K., Grattan, C., Baker, J., Li, H. H., Reshef, A., Bonner, J., Bernstein, J. A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613627 · Cited by 240
Autocrine Effects of Tumor-Derived Complement
Cho, M. S., Vasquez, H. G., Rupaimoole, R., Pradeep, S., Wu, S., Zand, B., Han, H.-D., Rodriguez-Aguayo, C., Bottsford-Miller, J., Huang, J., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.02.014 · Cited by 219
Abrera-Abeleda, M. A., Nishimura, C., Smith, J. L. H., Sethi, S., McRae, J. L., Murphy, B. F., Silvestri, G., Skerka, C., Józsi, M., Zipfel, P. F., et al. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2005.038315 · Cited by 216
Protection of host cells by complement regulators
Schmidt, C. Q., Lambris, J. D., & Ricklin, D. (2016) · Immunological Reviews · doi:10.1111/imr.12475 · Cited by 211
Self-citationImmune-suppressive properties of the tumor microenvironment
Becker, J. C., Andersen, M. H., Schrama, D., & thor Straten, P. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-013-1434-6 · Cited by 204
The CD46-Jagged1 interaction is critical for human TH1 immunity
Le Friec, G., Sheppard, D., Whiteman, P., Karsten, C. M., Shamoun, S. A.-T., Laing, A., Bugeon, L., Dallman, M. J., Melchionna, T., Chillakuri, C., et al. (2012) · Nature Immunology · doi:10.1038/ni.2454 · Cited by 204
Vadrevu, S. K., Chintala, N. K., Sharma, S. K., Sharma, P., Cleveland, C., Riediger, L., Manne, S., Fairlie, D. P., Gorczyca, W., Almanza, O., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0157 · Cited by 199
The Role of Complement in Tumor Growth
Pio, R., Corrales, L., & Lambris, J. D. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4614-5915-6_11 · Cited by 198
Self-citationTumor Vascular Proteins As Biomarkers in Ovarian Cancer
Buckanovich, R. J., Sasaroli, D., O'Brien-Jenkins, A., Botbyl, J., Hammond, R., Katsaros, D., Sandaltzopoulos, R., Liotta, L. A., Gimotty, P. A., & Coukos, G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8583 · Cited by 195
Wang, S.-Y., Racila, E., Taylor, R. P., & Weiner, G. J. (2008) · Blood · doi:10.1182/blood-2007-02-074716 · Cited by 194
S. Reis, E., Falcão, D. A., & Isaac, L. (2006) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2006.01729.x · Cited by 192
A functional variant in the CFI gene confers a high risk of age-related macular degeneration
van de Ven, J. P. H., Nilsson, S. C., Tan, P. L., Buitendijk, G. H. S., Ristau, T., Mohlin, F. C., Nabuurs, S. B., Schoenmaker-Koller, F. E., Smailhodzic, D., Campochiaro, P. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2640 · Cited by 187
Degn, S. E., Hansen, A. G., Steffensen, R., Jacobsen, C., Jensenius, J. C., & Thiel, S. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0902388 · Cited by 185
Surace, L., Lysenko, V., Fontana, A. O., Cecconi, V., Janssen, H., Bicvic, A., Okoniewski, M., Pruschy, M., Dummer, R., Neefjes, J., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.03.009 · Cited by 179
Villanueva, J., Martorella, A. J., Lawlor, K., Philip, J., Fleisher, M., Robbins, R. J., & Tempst, P. (2006) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m600229-mcp200 · Cited by 177
Ajona, D., Pajares, M. J., Corrales, L., Perez-Gracia, J. L., Agorreta, J., Lozano, M. D., Torre, W., Massion, P. P., de-Torres, J. P., Jantus-Lewintre, E., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt205 · Cited by 176
The “ins and outs” of complement‐driven immune responses
Freeley, S., Kemper, C., & Le Friec, G. (2016) · Immunological Reviews · doi:10.1111/imr.12472 · Cited by 161
Nevo, Y., Ben-Zeev, B., Tabib, A., Straussberg, R., Anikster, Y., Shorer, Z., Fattal-Valevski, A., Ta-Shma, A., Aharoni, S., Rabie, M., et al. (2013) · Blood · doi:10.1182/blood-2012-07-441857 · Cited by 159
Wang, Y., Sun, S.-N., Liu, Q., Yu, Y.-Y., Guo, J., Wang, K., Xing, B.-C., Zheng, Q.-F., Campa, M. J., Patz, E. F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1412 · Cited by 159
The immunoglobulin, IgG Fc receptor and complement triangle in autoimmune diseases
Karsten, C. M., & Köhl, J. (2012) · Immunobiology · doi:10.1016/j.imbio.2012.07.015 · Cited by 158
The tick-over theory revisited: Is C3 a contact-activated protein?
Nilsson, B., & Ekdahl, K. N. (2012) · Immunobiology · doi:10.1016/j.imbio.2012.07.008 · Cited by 157
Complement inhibition in cancer therapy
Pío, R., Ajona, D., & Lambris, J. D. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.04.001 · Cited by 147
Self-citationInnate immune mediators in cancer: between defense and resistance
Berraondo, P., Minute, L., Ajona, D., Corrales, L. P., Melero, I., & Pío, R. (2016) · Immunological Reviews · doi:10.1111/imr.12464 · Cited by 146
The role of the complement system in metabolic organs and metabolic diseases
Phieler, J., García-Martín, R., Lambris, J. D., & Chavakis, T. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.04.003 · Cited by 143
Self-citationWang, S., Veeramani, S., Racila, E. V., Cagley, J. R., Fritzinger, D. C., Vogel, C.-W., John, W. S., & Weiner, G. J. (2009) · Blood · doi:10.1182/blood-2009-01-200469 · Cited by 143
Is complement good or bad for cancer patients? A new perspective on an old dilemma
Markiewski, M. M., & Lambris, J. D. (2009) · Trends in Immunology · doi:10.1016/j.it.2009.04.002 · Cited by 139
Self-citationElvington, M. L., Liszewski, M. K., & Atkinson, J. P. (2016) · Immunological Reviews · doi:10.1111/imr.12474 · Cited by 139
Ascitic complement system in ovarian cancer
Bjørge, L., Hakulinen, J., Vintermyr, O., Jarva, H., Jensen, T. S., Iversen, O. E., & Meri, S. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602334 · Cited by 133
Nuñez-Cruz, S., Gimotty, P. A., Guerra, M. W., Connolly, D. C., Wu, Y., DeAngelis, R. A., Lambris, J. D., Coukos, G., & Scholler, N. (2012) · Neoplasia · doi:10.1593/neo.121262 · Cited by 133
Self-citationExpression of Complement Factor H by Lung Cancer Cells
Ajona, D., Castaño, Z., Garayoa, M., Zudaire, E., Pajares, M. J., Martínez, A., Cuttitta, F. F., Montuenga, L. M., & Pío, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2328 · Cited by 132
Nabizadeh, J., Manthey, H. D., Steyn, F. J., Chen, W., Widiapradja, A., Akhir, F. N. M., Boyle, G. M., Taylor, S. M., Woodruff, T. M., & Rolfe, B. E. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600210 · Cited by 131
C5a receptor‐deficient dendritic cells promote induction of Treg and Th17 cells
Weaver, D. J., Reis, E. S., Pandey, M. K., Köhl, G., Harris, N. L., Gerard, C. J., & Köhl, J. (2009) · European Journal of Immunology · doi:10.1002/eji.200939333 · Cited by 127
Self-citationClark, S. J., Schmidt, C. Q., White, A. M., Hakobyan, S., Morgan, B. P., & Bishop, P. N. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401613 · Cited by 122
Mamidi, S., Cinci, M., Hasmann, M., Fehring, V., & Kirschfink, M. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.02.011 · Cited by 122
Vitronectin-mediated inhibition of complement: evidence for different binding sites for C5b-7 and C9
Milis, L., Morris, C., Sheehan, M., et al. (1993) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.1993.tb05956.x · Cited by 121
Beurskens, F. J. M., Lindorfer, M. A., Farooqui, M. Z. H., Beum, P. V., Engelberts, P. J., Mackus, W. J. M., Parren, P. W. H. I., Wiestner, A. U., & Taylor, R. P. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103693 · Cited by 120
The complement system in cancer: Ambivalence between tumour destruction and promotion
Mamidi, S., Höne, S., & Kirschfink, M. (2015) · Immunobiology · doi:10.1016/j.imbio.2015.11.008 · Cited by 116
Phieler, J., Chung, K., Chatzigeorgiou, A., Ameln, A. K., García-Martín, R., Sprott, D., Moisidou, M., Tzanavari, T., Ludwig, B., Baraban, E., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300038 · Cited by 112
Self-citationSelf, Non-Self, and Danger: A Complementary View
Köhl, J. (2007) · Springer eBooks · doi:10.1007/0-387-34134-x_6 · Cited by 111
Piao, C., Cai, L., Qiu, S., Jia, L., Song, W., & Du, J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.612622 · Cited by 108
Chung, L., Moore, K., Phillips, L., Boyle, F. M., Marsh, D. J., & Baxter, R. C. (2014) · Breast Cancer Research · doi:10.1186/bcr3676 · Cited by 108
Ajona, D., Hsu, Y.-F., Corrales, L. P., Montuenga, L. M., & Pı́o, R. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.9.5991 · Cited by 107
McDonald, J. F., & Nelsestuen, G. L. (1997) · Biochemistry · doi:10.1021/bi962895r · Cited by 102
Opposing Roles for Complement Component C5a in Tumor Progression and the Tumor Microenvironment
Gunn, L., Ding, C., Liu, M., Ma, Y., Qi, C., Cai, Y., Hu, X., Aggarwal, D., Zhang, H., & Yan, J. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200846 · Cited by 101
Nitta, H., Wada, Y., Kawano, Y., Murakami, Y., Irie, A., Taniguchi, K., Kikuchi, K., Yamada, G., Suzuki, K., Honda, J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1204 · Cited by 99
Zent, C. S., Secreto, C. R., LaPlant, B. R., et al. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.05.014 · Cited by 98
Taylor, R. P., & Lindorfer, M. A. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.03.003 · Cited by 98
The role of complement component 3 (C3) in differentiation of myeloid-derived suppressor cells
Hsieh, C., Chou, H.-S., Yang, H.-R., Lin, F., Bhatt, S., Qin, J., Wang, L., Fung, J. J., Qian, S., & Lü, L. (2013) · Blood · doi:10.1182/blood-2012-06-440214 · Cited by 97
Increased Serum Levels of Complement C3a Anaphylatoxin Indicate the Presence of Colorectal Tumors
Habermann, J. K., Roblick, U. J., Luke, B. T., Prieto, D. A., Finlay, W. J. J., Podust, V. N., Roman, J. M., Oevermann, E., Schiedeck, T. H. K., Homann, N., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.07.011 · Cited by 97
Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells
Sherbenou, D. W., Aftab, B. T., Yang, S., Behrens, C. R., Wiita, A. P., Logan, A. C., Acosta‐Alvear, D., Hann, B. C., Walter, P., Shuman, M. A., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85856 · Cited by 97
Expression of complement components, receptors and regulators by human dendritic cells
Li, K., Fazekasova, H., Wang, N., Sagoo, P., Peng, Q., Khamri, W., Gomes, C., Sacks, S. H., Lombardi, G., & Zhou, W. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2011.02.003 · Cited by 96
Ning, C., Li, Y., Wang, Y., Han, G. C., Wang, R.-X., He, X., Li, X., Hou, C.-M., Ma, Y.-F., Sheng, D.-S., et al. (2015) · Mucosal Immunology · doi:10.1038/mi.2015.18 · Cited by 94
Complement Component 3 Is Regulated by TWIST1 and Mediates Epithelial–Mesenchymal Transition
Cho, M. S., Rupaimoole, R., Choi, H. J., Noh, K., Chen, J., Hu, Q., Sood, A. K., & Afshar‐Kharghan, V. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1501886 · Cited by 94
Díaz-Zaragoza, M., Hernández-Ávila, R., Viedma‐Rodríguez, R., Arenas-Aranda, D. J., & Ostoa‐Saloma, P. (2015) · Oncology Reports · doi:10.3892/or.2015.4095 · Cited by 92
Complement Component C3 and Complement Factor B Promote Growth of Cutaneous Squamous Cell Carcinoma
Riihilä, P., Nissinen, L. M., Farshchian, M., Kallajoki, M. A., Kivisaari, A., Meri, S., Grenman, R. A., Peltonen, S. A., Peltonen, J. T. K., Pihlajaniemi, T. A., et al. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.01.006 · Cited by 92
Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis
Hu, W., Ge, X., You, T., Xu, T., Zhang, J., Wu, G., Peng, Z., Chorev, M., Aktas, B. H., Halperin, J. A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3016 · Cited by 91
Spiller, O. B., Criado‐García, O., de Córdoba, S. R., et al. (2000) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2000.01305.x · Cited by 90
Complement anaphylatoxin C3a is a potent inducer of embryonic chick retina regeneration
Haynes, T., Luz-Madrigal, A., Reis, E. S., Echeverri Ruiz, N. P., Grajales-Esquivel, E., Tzekou, A., Tsonis, P. A., Lambris, J. D., & Del Rio-Tsonis, K. (2013) · Nature Communications · doi:10.1038/ncomms3312 · Cited by 87
Self-citationMedof, M. E., Gottlieb, A., Kinoshita, T., Hall, S., Silber, R., Nussenzweig, V., & Rosse, W. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci113043 · Cited by 85
Role of complement in host–microbe homeostasis of the periodontium
Hajishengallis, G., Abe, T., Maekawa, T., Hajishengallis, E., & Lambris, J. D. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.04.004 · Cited by 83
Self-citationComplement-triggered pathways orchestrate regenerative responses throughout phylogenesis
Mastellos, D. C., DeAngelis, R. A., & Lambris, J. D. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.04.002 · Cited by 83
Self-citationRondelli, T., Risitano, A. M., de Latour, R. P., Sica, M., Peruzzi, B., Ricci, P., Barcellini, W., Iori, A. P., Boschetti, C., Valle, V., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.090001 · Cited by 82
Okrój, M., Hsu, Y.-F., Ajona, D., Pı́o, R., & Blom, A. M. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.04.025 · Cited by 75
MAp19, the alternative splice product of the MASP2 gene
Degn, S. E., Thiel, S., Nielsen, O., Hansen, A. G., Steffensen, R., & Jensenius, J. C. (2011) · Journal of Immunological Methods · doi:10.1016/j.jim.2011.08.006 · Cited by 71
Geis, N. A., Zell, S., Rutz, R., Li, W., Giese, T., Mamidi, S., Schultz, S., & Kirschfink, M. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910793357952 · Cited by 71
Radiotherapy of Human Sarcoma Promotes an Intratumoral Immune Effector Signature
Sharma, A., Bode, B., Studer, G., Moch, H., Okoniewski, M. J., Knuth, A. K., von Boehmer, L., & van den Broek, M. F. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0352 · Cited by 69
Influence of the C5a–C5a receptor system on breast cancer progression and patient prognosis
Imamura, T., Yamamoto‐Ibusuki, M., Sueta, A., Kubo, T., Irie, A., Kikuchi, K., Kariu, T., & Iwase, H. (2015) · Breast Cancer · doi:10.1007/s12282-015-0654-3 · Cited by 67
van der Vlis, T. A. M. B., Trouw, L. A., Veerhuis, R., Dirven, C. M. F., Lamfers, M. L. M., & Al-Khawaja, H. (2014) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2014.11.016 · Cited by 66
Cancer cells release anaphylatoxin C5a from C5 by serine protease to enhance invasiveness
Nitta, H., Murakami, Y., Wada, Y., Eto, M., Baba, H., & Imamura, T. (2014) · Oncology Reports · doi:10.3892/or.2014.3341 · Cited by 65
Cook, E. M., Lindorfer, M. A., van der Horst, H. J., Oostindie, S. C., Beurskens, F. J. M., Schuurman, J., Zent, C. S., Burack, R., Parren, P. W. H. I., & Taylor, R. P. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600648 · Cited by 64
Bernabeu-Herrero, M. E., Jiménez-Alcázar, M., Anter, J., Pinto, S., Chinchilla, D. S., Garrido, S., López‐Trascasa, M., de Córdoba, S. R., & Sánchez‐Corral, P. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.06.021 · Cited by 63
A Complement–IL-4 Regulatory Circuit Controls Liver Regeneration
DeAngelis, R. A., Markiewski, M. M., Kourtzelis, I., Rafail, S., Syriga, M., Sandor, A., Maurya, M. R., Gupta, S., Subramaniam, S., & Lambris, J. D. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101925 · Cited by 60
Self-citationMaher, S. G., McDowell, D. T., Collins, B. C., Muldoon, C., Gallagher, W. M., & Reynolds, J. V. (2011) · Annals of Surgery · doi:10.1097/sla.0b013e31823699f2 · Cited by 60
An agonist of human complement fragment C5a enhances vaccine immunity against Coccidioides infection
Hung, C.-Y., Hurtgen, B. J., Bellecourt, M. J., Sanderson, S. D., Morgan, E. L., & Cole, G. T. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.04.084 · Cited by 59
Abdelbaset‐Ismail, A., Borkowska-Rzeszotek, S., Kubiś, E., Bujko, K., Brzeźniakiewicz‐Janus, K., Bołkuń, Ł., Kloczko, J. S., Moniuszko, M., Basak, G. W., Wiktor-Jędrzejczak, W., et al. (2016) · Leukemia · doi:10.1038/leu.2016.198 · Cited by 59
Complement-Dependent Modulation of Antitumor Immunity following Radiation Therapy
Elvington, M. L., Scheiber, M. N., Yang, X., Lyons, K., Jacqmin, D. J., Wadsworth, C., Marshall, D., Vanek, K. N., & Tomlinson, S. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.06.051 · Cited by 58
Baig, N. A., Taylor, R. P., Lindorfer, M. A., Church, A. K., LaPlant, B. R., Pettinger, A. M., Shanafelt, T. D., Nowakowski, G. S., & Zent, C. S. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302954 · Cited by 55
Anaphylatoxins coordinate innate and adaptive immune responses in allergic asthma
Schmudde, I., Laumonnier, Y., & Köhl, J. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.04.009 · Cited by 54
Doerner, S. K., Reis, E. S., Leung, E. S., Ko, J. S., Heaney, J. D., Berger, N. A., Lambris, J. D., & Nadeau, J. H. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0153 · Cited by 53
Self-citationC5a receptor (CD88) promotes motility and invasiveness of gastric cancer by activating RhoA
Kaida, T., Nitta, H., Kitano, Y., Yamamura, K., Arima, K., Izumi, D., Higashi, T., Kurashige, J., Imai, K., Hayashi, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12656 · Cited by 52
Bandini, S., Curcio, C., Macagno, M., Quaglino, E., Arigoni, M., Lanzardo, S., Hysi, A., Barutello, G., Consolino, L., Longo, D. L., et al. (2013) · OncoImmunology · doi:10.4161/onci.26137 · Cited by 50
Janelle, V., Langlois, M.-P., Tarrab, E., Lapierre, P., Poliquin, L., & Lamarre, A. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0173 · Cited by 50
Mohlin, F. C., Mercier, É., Frémeaux‐Bacchi, V., Liszewski, M. K., Atkinson, J. P., Gris, J., & Blom, A. M. (2013) · European Journal of Immunology · doi:10.1002/eji.201243196 · Cited by 48
Hakobyan, S., Tortajada, A., Harris, C. L., de Córdoba, S. R., & Morgan, B. P. (2010) · Kidney International · doi:10.1038/ki.2010.275 · Cited by 46
Evidence for in vivo Reaction of Antibody and Complement to Surface Antigens of Human Cancer Cells
Irie, K., Irie, R. F., & Morton, D. L. (1974) · Science · doi:10.1126/science.186.4162.454 · Cited by 45
Han, X., Zha, H., Yang, F., Guo, B., & Zhu, B. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010022 · Cited by 44
Complement component 3 is a prognostic factor of non-small cell lung cancer
Lin, K., He, S., HE, L., CHEN, J., Cheng, X., Zhang, G., & Zhu, B. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2230 · Cited by 43
Verma, M. K., Clemens, J. L., Burzenski, L. M., Sampson, S. B., Brehm, M. A., Greiner, D. L., & Shultz, L. D. (2017) · Journal of Immunological Methods · doi:10.1016/j.jim.2017.03.021 · Cited by 43
Complement Inhibition: A Novel Form of Immunotherapy for Colon Cancer
Downs‐Canner, S., Magge, D. R., Ravindranathan, R., O’Malley, M. E., Francis, L., Liu, Z., Guo, Z. S., Obermajer, N., & Bartlett, D. L. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4778-7 · Cited by 42
Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancer
Vlaicu, S. I., Tegla, C., Cudrici, C. D., Danoff, J., Madani, H., Sugarman, A. J., Niculescu, F. I., Mircea, P. A., Rus, V., & Rus, H. (2012) · Immunologic Research · doi:10.1007/s12026-012-8381-8 · Cited by 42
Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery
Mastellos, D. C., Reis, E. S., Ricklin, D., Smith, R. J., & Lambris, J. D. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.03.003 · Cited by 42
Self-citationSigler, C. S. (1997) · Archives of Dermatology · doi:10.1001/archderm.1997.03890440040006 · Cited by 38
Complement Membrane Attack and Tumorigenesis
Towner, L. D., Wheat, R. A., Hughes, T. R., & Morgan, B. P. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.708446 · Cited by 36
Complement in Antibody-Based Tumor Therapy
Derer, S., Beurskens, F. J. M., Rösner, T., Peipp, M., & Valerius, T. (2014) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2014009761 · Cited by 35
Michlmayr, A., Bachleitner‐Hofmann, T., Baumann, S., Marchetti‐Deschmann, M., Weichselbraun, I., Burghuber, C. K., Pluschnig, U., Bartsch, R., Graf, A. C., Greil, R., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605909 · Cited by 33
Xi, W., Liu, L., Wang, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13108 · Cited by 33
Impaired dendritic cell differentiation and maturation in the absence of C3
Reis, E. S., Barbuto, J. A. M., Köhl, J., & Isaac, L. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.10.031 · Cited by 31
Self-citationMikami, M., Tanabe, K., Matsuo, K., Miyazaki, Y., Miyazawa, M., Hayashi, M., Asai, S., Ikeda, M., Shida, M., Hirasawa, T., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.10.012 · Cited by 29
Manning, M. L., Williams, S. A., Jelinek, C., Kostova, M. B., & Denmeade, S. R. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1200856 · Cited by 28
A common CD55 rs2564978 variant is associated with the susceptibility of non-small cell lung cancer
Zhang, Y., Zhang, Z., Cao, L., Lin, J., Yang, Z., & Zhang, X. (2016) · Oncotarget · doi:10.18632/oncotarget.14053 · Cited by 28
Liang, T., Wang, N., Li, W., Li, A., Wang, J., Cui, J., Liu, N., Li, Y., Li, L., Yang, G., et al. (2009) · PROTEOMICS · doi:10.1002/pmic.200900513 · Cited by 27
Ishida, Y.-I., Yamashita, K., Sasaki, H., Takajou, I., Kubuki, Y., Morishita, K., Tsubouchi, H., & Okayama, A. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.06.004 · Cited by 27
Golay, J. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.06.002 · Cited by 15
Song, Q., Zhang, Z., Liu, Y., Han, S., & Zhang, X. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.10.006 · Cited by 14
Network-based analysis for identification of candidate genes for colorectal cancer progression
Tsuji, S., Midorikawa, Y., Seki, M., Takayama, T., Sugiyama, Y., & Aburatani, H. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.05.158 · Cited by 13
Karczmarski, J., Rubel, T., Mikuła, M., Wolski, J. K., Rutkowski, A., Zagórowicz, E., Dadlez, M., & Ostrowski, J. (2013) · Acta Biochimica Polonica · doi:10.18388/abp.2013_2002 · Cited by 12
Contractor, T., Kobayashi, S., da Silva, E. M., Clausen, R., Chan, C. H., Vosburgh, E., Tang, L. H., Levine, A. J., & Harris, C. R. (2016) · Oncotarget · doi:10.18632/oncotarget.8874 · Cited by 12
Cited by
Diversity, Mechanisms, and Significance of Macrophage Plasticity
Locati, M., Curtale, G., & Mantovani, A. (2020) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-012718 · Cited by 2,199
Self-citationMacrophages as tools and targets in cancer therapy
Mantovani, A., Allavena, P., Marchesi, F., & Garlanda, C. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00520-5 · Cited by 1,807
Self-citationNeutrophil diversity and plasticity in tumour progression and therapy
Jaillon, S., Ponzetta, A., Di Mitri, D., Santoni, A., Bonecchi, R., & Mantovani, A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0281-y · Cited by 1,285
Self-citationSu, S., Chen, J., Yao, H., Liu, J., Yu, S., Lao, L., Wang, M., Luo, M., Xing, Y., Chen, F., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.009 · Cited by 1,230
Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities
Xu, X., Zhang, M., Xu, F., & Jiang, S. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01276-5 · Cited by 588
Metadata
- Authors
- Reis, E. S., Mastellos, D. C., Ricklin, D., Mantovani, A., & Lambris, J. D.
- Venue
- Nature Reviews Immunology
- Published
- 2017-09-18
- Volume
- 18
- Issue
- 1
- Pages
- 5-18
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2754247840
- Cited by
- 425
- References
- 160
- FWCI
- 2.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.